若生智能
Drug Database
BE

betamethasone dipropionate (DFD01 / DFD 01 / Sernivo)

✓ Approved

Encore Dermatology, Inc. · 类固醇 · 类固醇

什么是 betamethasone dipropionate？

betamethasone dipropionate 是一种类固醇，由Encore Dermatology, Inc.研发。该药已获批，用于治疗相关适应症，给药途径：Topical。

药物档案

商品名DFD01, DFD 01, Sernivo
公司Encore Dermatology, Inc.
药物类别类固醇, 小分子
给药途径Topical
状态Approved
来源： ClinicalTrials.gov, Encore Dermatology, Inc.

治疗适应症

betamethasone dipropionate 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersPsoriasis✓ Approved

相关研究文献

PubMedEuropean journal of pain (London, England)2026-08-06

Catheter-Based Sacral Nerve Block Versus Pudendal Nerve Block in the Treatment of Pudendal Neuralgia: A Randomized Double-Blinded Controlled Trial.

Guo Kai-Kai KK, Li Jing J, Meng Ying Y, Wang Long L et al.

Pudendal neuralgia (PN) severely impacts quality of life, particularly sitting. Uncertainty exists whether catheter-based sacral nerve block with daily intermittent bolus (SNB) or pudendal nerve block (PNB) is more effective. This trial compared their efficacy over 6 months. A prospective, randomized, double-blinded trial in China enrolled 90 PN patients. Patients were randomized to CT-guided catheter-based PNB near the pudendal nerve or SNB through the third posterior sacral foramen. In both groups, the catheter remained in place for 7 days, and 10 mL of 0.2% ropivacaine was administered once daily as an intermittent bolus, with compound betamethasone administered on Day 7. Primary outcome was pain intensity (VAS) over 6 months; secondary outcomes included patient-reported global outcomes and maximum sitting time at 6 months. The SNB group had significantly lower VAS scores at 1 month (2.98 ± 1.47 vs. 3.72 ± 1.08, p = 0.04), 3 months (3.36 ± 1.14 vs. 4.17 ± 1.19, p = 0.02), and 6 months (3.85 ± 1.04 vs. 4.95 ± 1.08, p < 0.0001). Significantly more SNB patients reported excellent/good outcomes at 1 month (83.88% vs. 63.40%, p = 0.04) and 6 months (75.61% vs. 37.50%, p = 0.002). Maximum sitting time at 6 months was longer with SNB (68.56 ± 21.61 vs. 37.65 ± 16.25 min, p < 0.0001). No severe complications occurred. SNB provided superior and sustained pain relief, functional improvement, and patient satisfaction compared to PNB over 6 months in PN patients. Broader sacral root (S2-4) coverage by SNB may enhance efficacy by targeting pudendal neuropathy and central sensitization. SNB may be considered as an intermediate minimally invasive option for selected refractory PN patients in experienced centers, pending larger safety and feasibility studies. This first RCT directly comparing catheter-based nerve blocks for pudendal neuralgia demonstrates that sacral nerve block (SNB targeting S2-4) provides significantly superior and sustained pain relief, functional gains (doubled sitting tolerance), and patient satisfaction over pudendal nerve block (PNB) at 6 months. Its broader root coverage likely addresses central sensitization alongside neuropathy. Catheter-based sacral nerve block with daily intermittent bolus may represent an intermediate minimally invasive option for selected patients with refractory PN in experienced centers capable of structured catheter monitoring. Because this trial was not powered to estimate rare infectious complications and required a 7-day inpatient protocol, larger multicenter studies are needed to define safety, feasibility, cost-effectiveness, and the potential for outpatient adaptation.

PMID 42559665
阅读全文 →
PubMedPain physician2026-08-04

Safety and Effectiveness of Different Approaches for Epidural Steroid Injections in Lumbar Spinal Stenosis: A Systematic Review and Meta-Analysis.

Wilderman Igor I, Sarzetto Francesca F, Didari Tina T, Manor Rotem Frish RF et al.

Lumbar canal stenosis is a common degenerative disorder that causes pain and functional alterations. Epidural steroid injections (ESIs) are often used to treat the symptoms of this condition; however, treatment protocols can vary significantly, and no standardized practice for the management of lumbar canal stenosis has been established. To identify the optimal method of administration for maximizing the effectiveness and duration of pain relief and functionality improvements provided by ESIs. Systematic review and meta-analysis. We searched PubMed, Google Scholar, ScienceDirect, CINAHL, EMBASE, and OVID for clinical trials published from January 2000 to December 2025 that examined the effectiveness of different ESI protocols to ameliorate pain and functionality in spinal stenosis patients. The search terms included ("lumbar spinal stenosis" OR "lumbar canal stenosis" or "lumbar foraminal stenosis") AND "epidural steroid/corticosteroid injection(s)" AND ("interlaminar" OR "caudal" OR "transforaminal" OR "route"). Studies that met exclusion criteria were those that did not use human patients, that were not focused on lumbar stenosis, that had no consistent protocol, or did not express their outcomes as decreases in pain intensity. The risk of bias was assessed with the Cochrane RoB2 tool. We conducted a meta-analysis on the data from individual groups extracted from different studies, including sub-group and meta-regression analyses, to identify variables with significant effects. In total, 33 groups (comprising 1,350 patients) were extracted from 24 studies, with results from one week to 12 months after the injection. Most studies reported significant pain relief up to 3 months from the injections, and some reported that such pain relief persisted even after a year. Of all the factors that influenced the results, the type of steroid used had the greatest effect, with betamethasone providing the greatest and more prolonged relief. Triamcinolone and methylprednisolone offered similar initial levels of pain relief, though it decreased more rapidly, whereas dexamethasone showed the lowest level of benefits. Moreover, the pain relief effect was significantly weaker in patients with severe stenosis, and functionality improvements were also limited in patients with moderate/severe stenosis. In contrast, route of administration (transforaminal, interlaminar, or caudal), dose size, and other parameters showed no significant differences. Most groups included in the analysis were small, with 22 of the 33 (66.7%) having fewer than 50 patients, and only one group including more than 100. Furthermore, the results overall were significantly heterogeneous, and the follow-up times varied, meaning that some subgroups had only one result or none whatsoever at certain time points and limiting the subgroup analysis. ESIs are an effective treatment for the pain caused by spinal stenosis; betamethasone, even at a low dose, appears to provide the greatest benefits, whereas dexamethasone seems the least effective. Patients with mild or moderate stenosis are more likely to experience positive results from ESIs, and the administration route can be chosen depending on the patient's status, offering similar effects. The transforaminal route is likely more beneficial in single-level stenosis, while interlaminar (at the level of maximal stenosis or one caudad) and caudal injections are more appropriate for multilevel pathologies.

PMID 42550520
阅读全文 →
PubMedArchives of biochemistry and biophysics2026-08-04

GPR97-Gα12-mTORC1 signaling drives myotube hypertrophy: identification of 5-hydroxy-7-methoxyflavone as a pathway activator.

Fujita Shuhei S, Kimura Ayano A, Maekawa Daisuke D, Kubota Mai M et al.

Elucidating novel signaling pathways that drive myotube hypertrophy may provide new insights into the mechanisms regulating skeletal muscle growth. We previously reported that 5-hydroxy-7-methoxyflavone (HMF) induces hypertrophy of murine C2C12 myotubes; however, the underlying molecular mechanism remains unclear. Here, loss- and gain-of-function analyses revealed that GPR97 positively regulates myotube size. Furthermore, knockdown and rescue experiments demonstrated that GPR97 is required for HMF-induced myotube hypertrophy. HMF activated mTORC1 signaling in myotubes, and intramuscular administration of HMF also activated mTORC1 signaling in mouse skeletal muscle in vivo. Gpr97 knockdown abolished HMF-induced mTORC1 signaling and protein synthesis. Furthermore, depletion of Gna12 and expression of dominant-negative Gα12 abolished HMF-induced myotube hypertrophy. Gna12 depletion also suppressed HMF-induced mTORC1 signaling and protein synthesis. Beclomethasone dipropionate, a reported GPR97 ligand, suppressed HMF-induced hypertrophy and mTORC1 signaling, while further enhancing HMF-induced serum response factor (SRF)-dependent transcription. Although dominant-negative RhoA inhibited HMF-induced SRF-dependent transcriptional activity, it did not affect myotube hypertrophy. These findings indicate that GPR97-Gα12-mTORC1 signaling promotes hypertrophy independent of the Gα12-RhoA-SRF pathway. GPR97 was predominantly expressed on the myotube surface as a C-terminal fragment generated by N-terminal fragment (NTF) cleavage, and HMF reduced its surface expression. HMF induced hypertrophy in myotubes expressing an NTF cleavage-resistant GPR97 mutant, but not in those expressing an NTF-deleted mutant. These results indicate that NTF cleavage is dispensable and suggest that NTF contributes to GPR97-mediated hypertrophic signaling. These findings identify a novel GPR97-Gα12-mTORC1 signaling axis that mediates HMF-induced myotube hypertrophy.

PMID 42546894
阅读全文 →
PubMedExpert opinion on investigational drugs2026-08-03

Budigalimab: a viable option for patients with advanced solid tumors.

Mogenet Alice A, Greillier Laurent L

Immune checkpoint inhibitors transformed lung cancer treatment and prognosis, new drugs are currently being developed to continue to improve patient's outcome and especially surrogate immune checkpoint for each pharma company pipeline. We conducted a literature review on Budigalimab to describe current data on drug pharmacokinetics and pharmacodynamics alongside clinical efficacy and safety outcome. Budigalimab is a newly developed monoclonal antibody targeting programmed cell death 1 (PD1), enhanced with a Fc mutation to limit effector function in contrast to comparable drugs on the market. Phase I data successfully highlighted safety and expected efficacy as a single agent with flat dosage (250 mg Q2W, 375 Q3W or 500 mg Q4W) across various tumor types. Drug development is now focusing on combination strategies given the massive number of drugs in the pipeline. Phase II and phase III data are still pending but promising trials are currently running across various tumor types. Budigalimab is a new PD1 targeted immune checkpoint that is likely to be developed within association to other anticancer drugs within the Abbvie pipeline.

PMID 42544591
阅读全文 →
PubMedJournal of medical ultrasonics (2001)2026-08-02

Ultrasound-guided cervical selective nerve root block with or without steroid.

Iwata Shuhei S, Kojima Atsushi A, Hatakeyama Kenji K, Ohtori Seiji S

To compare short-term pain trajectories after ultrasound (US)-guided cervical selective nerve root block (SNRB) using a steroid-containing injectate versus a no-steroid injectate in patients with cervical radicular pain. This single-center prospective comparative study used time-period-based allocation of injectate. Consecutive patients undergoing a first-time US-guided cervical SNRB between 2021 and 2024 were reviewed. The steroid group received 1% lidocaine 1 mL + normal saline 2 mL + betamethasone 4 mg (1 mL). The no-steroid group received 1% lidocaine 1 mL + normal saline 3 mL. Pain intensity was assessed using the numerical rating scale (NRS; 0-10) at baseline, 15 min, day 1, day 2, and day 14. The primary analysis used a mixed model for repeated measures (MMRM) with group, time, and group-by-time interaction; the primary estimand was the between-group difference in change from baseline to day 14. Secondary analyses estimated between-group differences at each post-baseline time point. Safety outcomes included procedure-related complications and 3-month clinical course. Of 97 screened patients, 70 were analyzed (steroid: n = 43, no-steroid: n = 27). Baseline NRS was similar (6.98 ± 2.38 vs 6.93 ± 2.29). The group-by-time interaction was significant (p = 0.0036). At day 14, the steroid group showed greater improvement than the no-steroid group (MMRM between-group difference in change: - 1.55; p = 0.0077). Model-based differences favored steroid from 15 min through day 14. No procedure-related complications occurred; six patients underwent surgery during 3-month follow-up. In US-guided cervical SNRB, adding betamethasone was associated with superior short-term pain improvement without observed complications.

PMID 42541641
阅读全文 →
PubMedBiotechnology reports (Amsterdam, Netherlands)2026-08-02

Performance comparison of downstream unit operations and process chains for the purification of amino acids for food, feed and pharma applications.

Prachár Maximilián M, Buyel J F JF

Proteinogenic amino acids are important supplements in foods, feeds, and pharmaceuticals. However, the development of cost-efficient and scalable platform downstream processes for multi-ton manufacturing of amino acids is complicated by upstream process heterogeneity resulting in plethora of implementations at laboratory and industrial scale. Here, we review 18 unit operations and analyzed >50 downstream processes reported over six decades to compare separation performance, sustainability and costs, highlighting process advantages and limitations. We find that chromatography is used in >65% of downstream processes, achieving purities >98% in different setups. Sustainable and cost-effective alternatives seem to challenge this position. For example, membrane separations can achieve purities of 60-98% with reduced environmental footprint, costs, and additional options for process integration, mainly for acidic and basic amino acids. Crystallization is frequently used for formulation and purification if >50 g L-1 of amino acids with extreme pI are processed. Options to streamline current processes are discussed.

PMID 42541309
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多betamethasone dipropionate